The novel smallmolecule anticancer drug candidate licensed to SynCore Biotechnology has been approved for the Phase II clinical trial by TFDA and US FDA

NHRI licensed “the novel small-molecule anticancer drug candidate (DBPR104,as SB01)” to SynCore Biotechnology in 2008. SynCore Biotechnology was approved to implement the Phase 2 clinical trial targeting on Head and Neck Cancers by US FDA in April this year (2015) and immediately received the approval from TFDA in May. SynCore Biotechnology has planned to initiate the clinical trial at several medical centers in Taiwan and hope to provide a new option for the therapy of Head and Neck Cancer and benefits to patients.

Latest News from SynCore Biotechnology:

Share Button

Comments are closed.